PARSIPPANY, N.J. — Actavis last year gained approval for its Next Choice, a generic version of Teva Women’s Health’s Plan B One-Step, that now sits on top in emergency contraceptive sales. For the 52 weeks ended Oct. 6, Next Choice generated $115.2 million fueled by 20.2% growth. Plan B One-Step is ranked No. 2 with $96.4 million in sales, down 10.7%. Earlier this year, the FDA increased access to emergency contraceptives by no longer requiring that they be placed behind the pharmacy counter. However, for now, only Plan B One-Step can be sold to women younger than 17 years without a prescription.
Actavis’ Next Choice